4882.T
Perseus Proteomics Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 141.00
−0.70%Year over year
Reported trailing growth
- Revenue
- +25.0%
- EBITDA
- —
- EBIT
- +7.9%
- EPS
- +23.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -28.6%
- EBITDA
- —
- EPS
- -94.7%
Three-year CAGR
- Revenue
- +19.1%
- EBITDA
- +7.6%
- EBIT
- +7.6%
- Net income
- +18.1%
- EPS
- +32.3%
- Free cash flow
- +18.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026